Mizuno Tomoko, Inoshita Naoko, Fukuhara Noriaki, Tatsushima Keita, Takeshita Akira, Yamada Shozo, Nishioka Hiroshi, Takeuchi Yasuhiro
Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan.
Department of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Hospital, Japan.
Intern Med. 2022 Mar 1;61(5):679-685. doi: 10.2169/internalmedicine.6314-20. Epub 2021 Aug 31.
Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas.
帕瑞肽对生长抑素受体（SSTR）5具有高亲和力，作为难治性库欣病的一种新治疗方法已引起关注。该患者为一名28岁男性。他患有难治性库欣病，接受了多次手术、放疗和药物治疗。通过免疫组织化学对腺瘤进行检查，发现SSTR5表达较低。逆转录聚合酶链反应未检测到USP8突变。尽管我们给予了帕瑞肽，但无效。虽然需要进一步研究，但SSTR5表达分析可能有助于预测帕瑞肽对库欣病的疗效。我们报告此病例，作为考虑是否使用帕瑞肽治疗难治性促肾上腺皮质激素腺瘤时的有用参考。
